Israel Englander Reviva Pharmaceuticals Holdings, Inc. Transaction History

Millennium Management LLC

$213 Billion
Q3 2025

A detailed history of Israel Englander (Millennium Management LLC) transactions in Reviva Pharmaceuticals Holdings, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 1,711,221 shares of RVPH stock, worth $855,610. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,711,221

Previous 1,488,043 15.0%

Holding current value

$855,610

Previous $565,000 12.04%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$0.27 - $0.54 $60,258 - $120,516	223,178 Added 15.0%	1,711,221 $633,000
Q2 2025 Aug 14, 2025	SELL	$0.34 - $1.12 $15,733 - $51,826	-46,274 Reduced 3.02%	1,488,043 $565,000
Q1 2025 May 15, 2025	SELL	$0.95 - $2.08 $256,662 - $561,955	-270,171 Reduced 14.97%	1,534,317 $1.46 Million
Q4 2024 Feb 14, 2025	SELL	$0.92 - $2.82 $26,059 - $79,879	-28,326 Reduced 1.55%	1,804,488 $3.12 Million
Q3 2024 Nov 14, 2024	BUY	$0.64 - $1.48 $378,445 - $875,155	591,321 Added 47.63%	1,832,814 $2.64 Million

Q2 2024 Aug 14, 2024	BUY	$1.25 - $3.79 $483,620 - $1.47 Million	386,896 Added 45.27%	1,241,493 $1.59 Million
Q1 2024 May 15, 2024	BUY	$2.76 - $5.52 $145,427 - $290,854	52,691 Added 6.57%	854,597 $3.23 Million
Q4 2023 Feb 14, 2024	BUY	$3.56 - $6.04 $1.22 Million - $2.07 Million	342,230 Added 74.45%	801,906 $4.13 Million
Q2 2023 Aug 14, 2023	BUY	$4.42 - $8.55 $1.86 Million - $3.6 Million	421,241 Added 1095.98%	459,676 $2.69 Million
Q1 2023 May 15, 2023	BUY	$3.79 - $4.87 $145,668 - $187,178	38,435 New	38,435 $161,000

Others Institutions Holding RVPH

# of Institutions

Shares Held

9.74M

Call Options Held

585K

Put Options Held

31.6K

View Full List

About REVIVA PHARMACEUTICALS HOLDINGS, INC.

Ticker RVPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,442,900
Market Cap $10.2M
Description
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP506...

More about RVPH

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account